Immatics Provides Update on IMA204 ACTengine^® Cell Therapy Program Targeting the Tumor Microenvironment

Immatics N.V. has provided an update on its fourth ACTengine^® cell therapy program, IMA204. IMA204 is designed to address a novel target, COL6A3 exon 6, which is highly expressed in the stroma of a large number of solid tumors.